ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection

Xscientia plc today announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug

Juno Pharmaceuticals Canada a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories one of Canada’s largest domestic specialty

Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA®

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe

Kintor Pharmaceutical Limited a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house

Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals Co., Ltd. announced today that they entered into an exclusive global development

Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular

Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical